# Efficacy and Safety Study of Ultra-early Mobile Stroke Unit Neuroprotection Combined With Revascularization for Acute Ischemic Stroke (EXCELLENT)

Study · id `cardio:ct-nct07119021` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT07119021](<https://clinicaltrials.gov/study/NCT07119021>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT07119021

Browse, organ or system: Brain  
Browse, condition area: Stroke  

## In plain language

A phase 4 trial registered on ClinicalTrials.gov. The registry status is recruiting. It plans to enroll 300 participants.

## Technical summary

Registry record NCT07119021. Randomized; quadruple masking; primary purpose prevention. Start 2024-08-01 (actual); primary completion 2027-04-30 (anticipated). Results not posted.

## Key facts

- Design: Interventional study; randomized; quadruple masking; primary purpose prevention
- Phase: Phase 4
- Enrolled: 300 participants (planned count; ClinicalTrials.gov record NCT07119021, source copy `cardio:ctgov-nct07119021-2025-08-12`, retrieved 2026-10-26)
- Started: 2024-08-01 (actual) (ClinicalTrials.gov record NCT07119021, source copy `cardio:ctgov-nct07119021-2025-08-12`, retrieved 2026-10-26)
- Primary completion: 2027-04-30 (anticipated) (ClinicalTrials.gov record NCT07119021, source copy `cardio:ctgov-nct07119021-2025-08-12`, retrieved 2026-10-26)
- Completion: 2027-07-31 (anticipated) (ClinicalTrials.gov record NCT07119021, source copy `cardio:ctgov-nct07119021-2025-08-12`, retrieved 2026-10-26)
- Countries: China (ClinicalTrials.gov record NCT07119021, source copy `cardio:ctgov-nct07119021-2025-08-12`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "RECRUITING" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct07119021-2025-08-12`, retrieved 2026-10-26)

## The registry's words

- Brief title: Efficacy and Safety Study of Ultra-early Mobile Stroke Unit Neuroprotection Combined With Revascularization for Acute Ischemic Stroke (EXCELLENT)
- Acronym: EXCELLENT
- Condition: Ischemic Stroke
- Intervention (Drug): Intravenous thrombolysis + edaravone
- Intervention (Drug): IV thrombolysis + placebo (control group)
- Lead sponsor: Ruijun Ji
- Lead sponsor class: OTHER
- Collaborator: Xing'an League People's Hospital
- Collaborator class: UNKNOWN
- Collaborator: The First Affiliated Hospital of Soochow University
- Collaborator class: OTHER
- Collaborator: Nanyang Nanshi Hospital
- Collaborator class: OTHER
- Collaborator: Nanjing Baixinyu Pharmaceutical Co., Ltd.
- Collaborator class: UNKNOWN

## Connected pages

- Registry condition terms include this condition: Ischemic stroke (`cardio:ischemic-stroke`)
- Registry condition terms include this condition: Stroke (`core:stroke`)
- Registry lists this organization as a collaborator: The First Affiliated Hospital of Soochow University (`cardio:org-the-first-affiliated-hospital-of-soochow-university`)
- Registry lists this organization as a collaborator: Nanyang Nanshi Hospital (`cardio:org-nanyang-nanshi-hospital`)

## Provenance

Content hash: 91d7d666242193692e4cb9e3add754b00b43d830ae1544f35863e4db00c97eb6
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
